Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, Copland M, Brassat U, Priemer M, Hauber I, Wilhelm T, Schwarz G, Kanz L, Bokemeyer C, Hauber J, Holyoake TL, Nordheim A, Brümmendorf TH. Balabanov S, et al. Among authors: brummendorf th. Blood. 2007 Feb 15;109(4):1701-11. doi: 10.1182/blood-2005-03-037648. Epub 2006 Sep 28. Blood. 2007. PMID: 17008552 Free article.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH. Gontarewicz A, et al. Among authors: brummendorf th. Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11. Blood. 2008. PMID: 18268096 Free article.
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH. Gontarewicz A, et al. Among authors: brummendorf th. Leuk Res. 2008 Dec;32(12):1857-65. doi: 10.1016/j.leukres.2008.04.012. Epub 2008 Jun 2. Leuk Res. 2008. PMID: 18514829
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M. Cortes J, et al. Among authors: brummendorf th. Leukemia. 2008 Dec;22(12):2176-83. doi: 10.1038/leu.2008.221. Epub 2008 Aug 28. Leukemia. 2008. PMID: 18754032 Clinical Trial.
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski GB, Schafhausen P, Zander AR, Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf TH, Kröger N, Bacher U. Ocheni S, et al. Among authors: brummendorf th. Leuk Lymphoma. 2009 Apr;50(4):551-8. doi: 10.1080/10428190902755513. Leuk Lymphoma. 2009. PMID: 19373652
Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).
Klyuchnikov E, Kröger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U. Klyuchnikov E, et al. Among authors: brummendorf th. Biol Blood Marrow Transplant. 2010 Mar;16(3):301-10. doi: 10.1016/j.bbmt.2009.08.019. Epub 2009 Sep 8. Biol Blood Marrow Transplant. 2010. PMID: 19744571 Free article. Review.
362 results